H. Savli Et Al. , "Bortezomib combined with histone deacetylase inhibitor ITF2357 or arsenic trioxide exerts aynergistic anti-proliferative and pro-apoptotic effect on P39 cells," JOURNAL OF CLINICAL ONCOLOGY , vol.26, no.15, 2008
Savli, H. Et Al. 2008. Bortezomib combined with histone deacetylase inhibitor ITF2357 or arsenic trioxide exerts aynergistic anti-proliferative and pro-apoptotic effect on P39 cells. JOURNAL OF CLINICAL ONCOLOGY , vol.26, no.15 .
Savli, H., Galimberti, S., Canestraro, M., Nagy, B., Palumbo, G. A., & Petrini, M., (2008). Bortezomib combined with histone deacetylase inhibitor ITF2357 or arsenic trioxide exerts aynergistic anti-proliferative and pro-apoptotic effect on P39 cells. JOURNAL OF CLINICAL ONCOLOGY , vol.26, no.15.
Savli, H. Et Al. "Bortezomib combined with histone deacetylase inhibitor ITF2357 or arsenic trioxide exerts aynergistic anti-proliferative and pro-apoptotic effect on P39 cells," JOURNAL OF CLINICAL ONCOLOGY , vol.26, no.15, 2008
Savli, H. Et Al. "Bortezomib combined with histone deacetylase inhibitor ITF2357 or arsenic trioxide exerts aynergistic anti-proliferative and pro-apoptotic effect on P39 cells." JOURNAL OF CLINICAL ONCOLOGY , vol.26, no.15, 2008
Savli, H. Et Al. (2008) . "Bortezomib combined with histone deacetylase inhibitor ITF2357 or arsenic trioxide exerts aynergistic anti-proliferative and pro-apoptotic effect on P39 cells." JOURNAL OF CLINICAL ONCOLOGY , vol.26, no.15.
@article{article, author={H. Savli Et Al. }, title={Bortezomib combined with histone deacetylase inhibitor ITF2357 or arsenic trioxide exerts aynergistic anti-proliferative and pro-apoptotic effect on P39 cells}, journal={JOURNAL OF CLINICAL ONCOLOGY}, year=2008}